Abstract

ACP Journal ClubOctober 15, 2013Apixaban was noninferior to enoxaparin plus warfarin in patients with acute venous thromboembolismThomas DeLoughery, MD, FACP, FAWMThomas DeLoughery, MD, FACP, FAWMOregon Health & Science University, Portland, Oregon, USA (T.D.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-159-8-201310150-02002 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationAgnelli G, Buller HR, Cohen A, et al; Amplify Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808. https://pubmed.ncbi.nlm.nih.gov/23808982Clinical Impact RatingsEmergency Med: Hematology: References1 Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-52. [PMID: 19966341] Google Scholar2 EINSTEIN Investigators, Bauersachs R, Berkowitz SD, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-510. [PMID: 21128814] Google Scholar3 EINSTEIN–PE Investigators, Büller HR, Prins MH, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-97. [PMID: 22449293] Google Scholar4 Lu G, DeGuzman FR, Hollenbach SJ, et al. A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med. 2013;19:446-51. [PMID: 23455714] Google Scholar Author, Article, and Disclosure InformationAffiliations: Oregon Health & Science University, Portland, Oregon, USA (T.D.) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics October 15, 2013Volume 159, Issue 8Page: JC2 Issue Published: October 15, 2013 Copyright & PermissionsCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.